Skip to main content
Equibles
GDRX logo

GDRX · GoodRx Holdings, Inc. · Documents

Track GDRX — free

Use GDRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GDRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.51 +0.02 (+0.57%) At close · Nov 6 Play latest call Q2 2026 earnings call transcript
Rebalance outlook locked
Market Cap
$1.19B
Shares
341.15M
Volume · Nov 6 1.17M Avg daily vol (3M) 1.23M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $796.85M up 0.6% 10-K filed Feb 26, 2026 Quarterly report FY2026 Q2 Revenue $200.41M down 1.3% 10-Q filed Aug 5, 2026 Latest results Financial results 8-K filed Aug 5, 2026 Earnings call Q2 2026 earnings call Held Aug 6, 2026
2026
Nov 2
Current report 8-K Events of Oct 27
Earlier financial statements no longer reliable

GoodRx Holdings, Inc. will restate financial statements for the six months ended June 30, 2026 after understating Pharma Direct revenue; total revenue (in thousands) rises from 394,417 to 424,190, and net income from 9,705 to 24,552.

Aug 5
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $200.41M ▼ 1.3% Net income $8.54M ▼ 33.5% Diluted EPS $0.02 ▼ 50.0%
May 6
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $194.01M ▼ 4.4% Net income $1.17M ▼ 89.4% Diluted EPS $0.00
Feb 26
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $796.85M ▲ 0.6% Net income $30.44M ▲ 85.7% Diluted EPS $0.09 ▲ 125.0%
2025
Nov 4
Quarterly report 10-Q FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Revenue $196.03M ▲ 0.4% Net income $1.12M ▼ 71.8% Diluted EPS $0.00
Aug 6
Quarterly report 10-Q FY2025 Q2, ended Jun 30
Quarterly report for FY2025 Q2
Revenue $203.07M ▲ 1.2% Net income $12.84M ▲ 91.9% Diluted EPS $0.04 ▲ 100.0%
Feb 27
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $792.32M ▲ 5.6% Net income $16.39M Diluted EPS $0.04
2024
Showing 1–50 of 146 documents
Key facts CIK 1809519 CUSIP 38246G108 13F (30d) 78 filings 66 filers Visit website Investor relations